. Author manuscript; available in PMC: 2015 Aug 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2014 Apr 13;20(8):1121–1129. doi: 10.1016/j.bbmt.2014.03.032

Table 4.

Association of day +21 IMPDH AUEC with HCT outcomes

	Events^a	OR/HR^b (95% CI)	P-value
Day +28 T-cell chimerism ≥95%	23	0.96 (0.4–2.6)	0.96
Grade 2–4 acute GVHD	33	0.72 (0.4–1.3)	0.26
Grade 3–4 acute GVHD	4	0.13 (0.0–1.0)	0.05
Extensive chronic GVHD	30	1.38 (0.7–2.9)	0.38
Relapse	10	0.95 (0.3–3.2)	0.93
CMV reactivation	21	0.29 (0.1–0.7)	0.003
Non-relapse mortality	9	0.23 (0.1–1.0)	0.04
Overall mortality	17	0.40 (0.2–0.9)	0.03

Events on or after day +26.

Day +28 T-cell chimerism analyzed as binary endpoint (OR), all others as time-to-event endpoint (HR). OR and HR are effects per doubling of IMPDH AUEC. All analyses adjusted for Kahl relapse risk category (low, standard, high), donor-recipient gender (female to male, other), and donor (related, unrelated).